Company / Revenue per Share
Amylyx Pharmaceuticals, Inc. Revenue per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
-
FY2025
5-year range
$0.00 / $5.62
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#147 of 154
Health Care
What the data says
Declined from $5.62 to $0.00 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 154
▼
Key checks
Key Insights
- In FY2025, revenue per share decreased 100.0% year-over-year.
- Peak revenue per share was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.00 | -100.0% |
| FY2024 | $1.27 | -77.4% |
| FY2023 | $5.62 | +77.6% |
| FY2022 | $3.17 | +7217.7% |
| FY2021 | $0.04 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026